Pharmacological Treatments of Parkinson's Disease-Reference-Cited by-同舟云学术

Pharmacological Treatments of Parkinson's Disease

Published:2023-08-04 Issue: Volume: Page:220-232
ISSN:2475-6628
Container-title:Experimental and Clinical Evidence of the Neuropathology of Parkinson’s Disease
language:
Short-container-title:

Author:

Tamegart Lahcen¹,Oukhrib Mjid²^ORCID,Oudghiri Dia Eddine¹^ORCID,El-Mansoury Bilal³,Ibtissam Chakir⁴,Draoui Ahmed²^ORCID,El Ghachi Hafida²^ORCID,Ben Maloui Abdelali⁵,El Khiat Abdelaati⁶,Gamrani Halima⁵

Affiliation:

1. Biology and Health Unit, Department of Biology, Faculty of Science, Abdelmalek Essaâdi University, Morocco

2. Faculty of Sciences Semlalia, Cadi Ayyad University, Morocco

3. Department of Biology, Faculty of Science, Chouaib Doukkali University, Morocco

4. Polydisciplinary Faculty of Beni Mellal, Sultan Moulay Slimane University, Morocco

5. Independent Researcher, Morocco

6. Higher Institute of Nursing Professions and Health Techniques, Ouarzazate, Morocco

Abstract

Parkinson's disease (PD) is recognized as the second most common neurodegenerative disease after Alzheimer's disease. Parkinson's disease is a progressive disease characterized by a progressive loss of dopaminergic neurons of the black substance (SNpc) and dopamine deficiency in the striatal region as well as motor and non-motor symptoms. The main objective of Parkinson's research is to understand the pathogenesis, targets, and development of therapeutic interventions to control disease progression. The use of various agents could be a good strategy for the treatment of PD.

Publisher

IGI Global

Reference57 articles.

1. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease

2. Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysis

3. Parkinson disease

4. Pergolide monotherapy in the treatment of early PD: A randomized, controlled study

5. Nonmotor Disturbances in Parkinson’s Disease